LogicBio Therapeutics (LOGC) Misses Q1 EPS by 27c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- Dow, S&P 500 fall, tech steadies to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Brent crude jumps to highest since April on Houthi attacks, UAE oil spill
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts LOGC Hot Sheet
Price: $7.06 --0%
EPS Growth %: +42.9%
Financial Fact:
Gross margin: 151.4K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
EPS Growth %: +42.9%
Financial Fact:
Gross margin: 151.4K
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
LogicBio Therapeutics (NASDAQ: LOGC) reported Q1 EPS of ($0.27).
For earnings history and earnings-related data on LogicBio Therapeutics (LOGC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta's Muse AI to counter China models with subscribers, not ads, Alexandr Wang says - Nikkei
- U.S. to remove 50% tariff on some Canadian products - WSJ
- Goldman Sachs sees US stocks dip on tech earnings and macro shifts
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
